Marco Bortolato1, Consuelo Walss-Bass2, Peter M Thompson3, Jackob Moskovitz4. 1. a Department of Pharmacology and Toxicology, College of Pharmacy , University of Utah , Salt Lake City , UT , USA. 2. b Department of Psychiatry and Behavioral Science, School of Medicine , University of Texas Health Science Center , Houston , TX , USA. 3. c Southwest Brain Bank, Department of Psychiatry , Texas Tech University Health Science Center at El Paso , El Paso , TX , USA. 4. d Department of Pharmacology and Toxicology, School of Pharmacy , University of Kansas , Lawrence , KS , USA.
Abstract
OBJECTIVES: The enzyme catechol-O-methyltransferase (COMT), which catalyses the degradation of dopamine and norepinephrine, is posited to participate in the pathophysiology of bipolar disorder (BD) and schizophrenia. In support of this notion, rich evidence has documented that the severity of various BD and schizophrenia symptoms is moderated by rs4680, a single nucleotide polymorphism of the COMT gene featuring a valine (Val)-to-methionine (Met) substitution that results in lower catalytic activity. Nevertheless, the specific relevance of COMT enzymatic activity in the pathophysiology of BD and schizophrenia dimensions remains elusive. METHODS: We measured COMT catalytic activity in post-mortem prefrontal cortices, striata and cerebella of schizophrenia and BD patients, as well as non-affected controls. These values were then correlated with rs4680 genotypes and psychopathology scores in the last week of life. RESULTS: No direct correlation between COMT activity and rs4680 genotypes was found; however, the severity of manic symptoms was highly correlated with COMT activity in the striatum, irrespective of the diagnostic group. CONCLUSIONS: These results suggest that COMT striatal activity, but not rs4680 genotype, may serve as a biomarker for manic symptoms. Future studies are warranted to confirm these findings and assess the neurobiological links between COMT striatal activity and manic symptoms.
OBJECTIVES: The enzyme catechol-O-methyltransferase (COMT), which catalyses the degradation of dopamine and norepinephrine, is posited to participate in the pathophysiology of bipolar disorder (BD) and schizophrenia. In support of this notion, rich evidence has documented that the severity of various BD and schizophrenia symptoms is moderated by rs4680, a single nucleotide polymorphism of the COMT gene featuring a valine (Val)-to-methionine (Met) substitution that results in lower catalytic activity. Nevertheless, the specific relevance of COMT enzymatic activity in the pathophysiology of BD and schizophrenia dimensions remains elusive. METHODS: We measured COMT catalytic activity in post-mortem prefrontal cortices, striata and cerebella of schizophrenia and BD patients, as well as non-affected controls. These values were then correlated with rs4680 genotypes and psychopathology scores in the last week of life. RESULTS: No direct correlation between COMT activity and rs4680 genotypes was found; however, the severity of manic symptoms was highly correlated with COMT activity in the striatum, irrespective of the diagnostic group. CONCLUSIONS: These results suggest that COMT striatal activity, but not rs4680 genotype, may serve as a biomarker for manic symptoms. Future studies are warranted to confirm these findings and assess the neurobiological links between COMT striatal activity and manic symptoms.
Entities:
Keywords:
Catechol-O-methyltransferase; bipolar disorder; manic symptoms; schizophrenia; single nucleotide polymorphism
Authors: Ting Ting Chang; Tzung Lieh Yeh; Nan Tsing Chiu; Po See Chen; Hsiang Yu Huang; Yen Kuang Yang; I Hui Lee; Ru Band Lu Journal: Bipolar Disord Date: 2010-02 Impact factor: 6.744
Authors: B Gutiérrez; J Bertranpetit; R Guillamat; V Vallès; M J Arranz; R Kerwin; L Fañanás Journal: Am J Psychiatry Date: 1997-01 Impact factor: 18.112
Authors: C L Bowden; V Singh; P Thompson; J M Gonzalez; M M Katz; M Dahl; T J Prihoda; X Chang Journal: Acta Psychiatr Scand Date: 2007-09 Impact factor: 6.392
Authors: G Kirov; K C Murphy; M J Arranz; I Jones; F McCandles; H Kunugi; R M Murray; P McGuffin; D A Collier; M J Owen; N Craddock Journal: Mol Psychiatry Date: 1998-07 Impact factor: 15.992
Authors: H Kunugi; H P Vallada; F Hoda; G Kirov; M Gill; K J Aitchison; D Ball; M J Arranz; R M Murray; D A Collier Journal: Biol Psychiatry Date: 1997-08-15 Impact factor: 13.382